Telomir Pharmaceuticals Develops Innovative Silver(II) Antimicrobial Drug Candidate

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity

Antimicrobial resistance is recognized as one of the top global public health threats, and Telomir-Ag2 strengthens Telomir's pipeline with a differentiated candidate designed to address this urgent and expanding crisis

Telomir Pharmaceuticals Develops Innovative Silver(II) Antimicrobial Drug Candidate

Telomir Pharmaceuticals has unveiled a promising new antimicrobial drug candidate, Telomir-Ag2, which represents a significant advancement in combating drug-resistant infections. Developed using the company’s proprietary Telomir-1 platform, this stabilized Silver(II) complex demonstrates broad-spectrum antimicrobial activity, including effectiveness against challenging infections like methicillin-resistant Staphylococcus aureus (MRSA). The drug …